Apogee Enterprises Inc

APOG remains in a Stage 2 advance with a bullish medium-term bias, but recent support failure and a down-sloping short-term EMA regime make immediate entry inadvisable. Price is holding above the rising 50 DMA, offering a structurally relevant zone for potential engagement. Until short-term momentum shows signs of stabilization and reclaim of the 9/21 EMAs, execution should be deferred with a stalking posture.

• ↑Q1 net sales $342.7M; adjusted diluted EPS $0.57 exceeded est.
• ↑Kalwall acquisition adds high-performance daylighting and cross-sell synergies.
• ↓Q1 net sales down 4.5% YoY to $346M; backlog fell to $720M.